Background: A head to head comparison study on renal function and ductal response between indomethacin and ibuprofen has rarely been conducted in extremely low birth weight (ELBW) infants. Objectives: The aim was to compare renal function and ductal response between indomethacin and ibuprofen in ELBW infants. Methods: We performed a double-blind randomized control trial to compare renal function and ductal response between indomethacin (0.2, 0.1, and 0.1 mg/kg i.v. every 24 h for 3 doses) and ibuprofen lysine (10, 5, and 5 mg/kg i.v. every 24 h for 3 doses) in ELBW infants with significant hemodynamic patent ductus arteriosus (cardiovascular dysfunction score >3 and LA/AO ratio ≥1.3). Results: A total of 144 infants were enrolled: 73 received indomethacin and 71 received ibuprofen lysine. Significant decreases in urine output were seen in 30 infants (41%) in the indomethacin group and 15 (21%) in the ibuprofen group (p = 0.02). The indomethacin group was associated with a significantly higher chance of persistent ductal response than the ibuprofen group (66 vs. 49%, p = 0.046), but with a lower glomerular filtration rate on day 1, higher serum creatinine on days 1, 2, and 7, and lower urinary prostaglandin on days 2-7. Both groups were comparable in mortality and in bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity morbidity. Conclusions: With the current dosage, ibuprofen had fewer renal side effects but was associated with a lower rate of persistent ductal closure in ELBW infants. The precise role of prostaglandin on renal tubular function in ELBW infants remains to be further investigated.

Keywords:
Patent ductus arteriosus, Extremely low birth weight infants, Indomethacin, Ibuprofen
1.
Clyman RI: Ibuprofen and patent ductus arteriosus. N Engl J Med 2000;343:728-730.
2.
Jones LJ, Craven PD, Attia J, Thakkinstian A, Wright I: Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F45-F52.
3.
Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD: Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000;47:36-42.
4.
Thomas RL, Parker GC, van Overmeire B, Aranda JV: A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005;164:135-140.
5.
van Overmeire B, Smets K, Lecoutere D, van de Broek H, Weyler J, Degroote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343:674-681.
6.
Yeh TF, Raval D, Luken J, Thalji A, Lilien L, Pildes RS: Clinical evaluation of premature infants with patent ductus arteriosus: a scoring system with echocardiogram, acid-base, and blood gas correlations. Crit Care Med 1981;9:655-657.
7.
Yeh TF, Achanti B, Patel H, Pildes RS: Indomethacin therapy in premature infants with patent ductus arteriosus - determination of therapeutic plasma levels. Dev Pharmacol Ther 1989;12:169-178.
8.
Fleiss JL, Levin B, Paik MC (eds): Statistical Methods for Rates and Proportions, ed 3. New York, John Wiley and Sons, 2003, pp 64-85.
9.
Ohlsson A, Walia R, Shah SS: Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2015;CD003481.
10.
Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS: Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.
11.
van Overmeire B, Allegaert K, Casaer A, Debauche C, Decaluwe W, Jespers A, Weyler J, Harrewijn I, Langhendries JP: Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1945-1949.
12.
Yeh TF, Luken JA, Thalji A, Raval D, Carr I, Pildes RS: Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus - a double-blind controlled study. J Pediatr 1981;98:137-145.
13.
Yeh TF, Luken J, Raval D, Thalji A, Carr I, Pildes RS: Indomethacin treatment in small versus large premature infants with ductus arteriosus: comparison of plasma indomethacin concentration and clinical response. Br Heart J 1983;50:27-30.
14.
Clyman RI: Mechanisms regulating the ductus arteriosus. Biol Neonate 2006;89:330-335.
15.
Drukker A, Guignard JP: Ibuprofen-lysine for closure of patent ductus arteriosus. Acta Paediatr 2001;90:465-466.
16.
Hirt D, van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S: An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008;65:629-636.
17.
Guignard JP, Drukker A: Why do newborn infants have a high plasma creatinine? Pediatrics 1999;103:e49.
18.
Reyes JL, Melendez E: Effects of eicosanoids on the water and sodium balance of the neonate. Pediatr Nephrol 1990;4:630-634.
19.
DeWitt DL, Meade EA, Smith WL: PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95:40S-44S.
20.
Gleason CA: Prostaglandins and the developing kidney. Semin Perinatol 1987;11:12-21.
21.
Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D: Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-25938.
22.
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
23.
Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
24.
Bancalari E, Claure N, Gonzalez A: Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88:192-201.
25.
Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL: Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 2000;105:320-324.
26.
Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS: Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics 1981;68:99-102.
27.
Antonucci R, Cuzzolin L, Arceri A, Fanos V: Urinary prostaglandin E2 in the newborn and infant. Prostaglandins Other Lipid Mediat 2007;84:1-13.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.